GENETIC ASPECTS OF PROGNOSIS OF EFFICIENCY AND SAFETY OF PHARMACOTHERAPY OF ATOPIC BRONCHIAL ASTHMA IN CHILDREN
The article presents data on the effectiveness of pharmacogenetic markers of treatment efficacy in children with atopic bronchial asthma. Variability in response to treatment with glucocorticosteroids, leukotriene receptor antagonists and ß2-adrenergic agonists in children with bronchial asthma is disclosed. The association of Gly/Gly16 genotype of ß2-adrenergic receptor gene with insufficient effect of the therapy with short-acting ß2-agonists is demonstrated. The involvement of Gly16 allele, CYP2D6*1934GGd, in development of phenotype with severe asthma tolerant to therapy with ß2-agonists and inhaled corticosteroids is emphasized.